The role of compliance in the treatment of chronic heart failure and the ways to improve it
Natalia S. Meshcherina,
Elena M. Khardikova,
Nina K. Gorshunova,
Natalia V. Abrosimova,
Tatyana S. Leontieva https://doi.org/10.21626/vestnik/2021-3/01
Abstract
Despite the development and implementation of clinical guidelines, emergence of modern effective drugs for the treatment of chronic heart failure (CHF), this pathology is characterized by stable progression, directly worsening the quality of life and decreasing the life expectancy. With that, treatment efficacy directly depends on high treatment compliance in patients with CHF both at the treatment start and upon its subsequent correction. One should also not underestimate the value of patient readiness to modify their lifestyle. Besides, the complete physician compliance with clinical guidelines also plays a significant role. The absence of correspondence between principles defined in the guidelines and really administered drugs excludes the possibility of achieving control over CHF symptoms and positive impact on the prognosis. This review is aimed at evaluating treatment compliance among both patients with CHF and their physicians with a focus on Russian studies and good clinical practice (GCP) compared to studies of foreign authors. Unfortunately, the problem of compliance in CHF in the Russian Federation has not been sufficiently analyzed in large-scale studies up to the present time: CHF patient registries mainly allow to detect clinical and epidemiological disease features, while almost not covering compliance issues. It should also be noted that the problem of compliance in both physicians and patients is undoubtedly up-to-date, as it often defines further prognosis in patients with CHF, which explains the scientific practical value of large trials with subsequent thorough analysis and searches regarding increasing its efficiency.
About the Authors
Natalia S. Meshcherina
Kursk State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Associate Professor, Vice-Rector for Continuous Education and International Cooperation, Head of the Department of Internal Diseases No. 1
Elena M. Khardikova
Kursk State Medical University
Russian Federation
Russian Federation
Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Internal Diseases No. 1
Nina K. Gorshunova
Kursk State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Professor of the Department of Polyclinic Therapy and General Practice
Natalia V. Abrosimova
Kursk State Medical University
Russian Federation
Russian Federation
Lecturer Assistant of the Department of Polyclinic Therapy and General Medical Practice
Tatyana S. Leontieva
Kursk State Medical University
Russian Federation
Russian Federation
Lecturer Assistant of the Department of Internal Diseases No. 1
References
1. Bunova S.S., Zhernakova N.I., Skirdenko Yu.P., Nikolaev N.A. Adherence to therapy, lifestyle modification and medical support of cardiovascular patients. Cardiovascular Therapy and Prevention. 2020;19(6):38-42 (in Russ.). DOI: 10.15829/1728-8800-2020-2665
2. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu., Drapkina O.M. Questionnaires and scores for assessing medication adherence - advantages and disadvantages of the diagnostic method in research and actual clinical practice. Cardiovascular Therapy and Prevention. 2020;19(3):232-239 (in Russ.). DOI: 10.15829/1728-8800-2020-2562
3. Lukina Y.V., Martsevich S.Yu., Kutishenko N.P. The Morisky-Green scale: the pros and cons of universal test, correction of mistakes. Rational Pharmacotherapy in Cardiology. 2016;12(1): 63-65 (in Russ.). DOI: 10.20996/1819-6446-2016-12-1-63-65
4. Loukianov M.M., Kozminsky A.N., Martsevich S.Yu., Yakushin S.S., Vorobyev A.N., Zagrebelnyy A.V., Myasnikov R.P., Pereverzeva K.G. et al. Patients with combination of chronic heart failure, hypertension and history of myocardial infarction: clinical and anamnestic characteristics, administration of ace inhibitors, angiotensin receptor blockers, β-blockers and adherence to the drug therapy (data of outpatient registry RECVASA). Rational Pharmacotherapy in Cardiology. 2017;13(2):207-212 (in Russ.). DOI: 10.20996/1819-6446-2017-13-2-207-212
5. Martsevich S.Yu., Kutishenko N.P., Lukina Yu.V., Lukyanov M.M., Drapkina O.M. Clinical trials evaluating drug therapy: types, reliability of results, place in modern evidence-based medicine. Rational Pharmacotherapy in Cardiology. 2021; 17(2):249-255 (in Russ.). DOI: 10.20996/1819-6446-2021-04-07
6. Nikishchenkova I.V., Nikiforov V.S. The influence of adherence to treatment on myocardial dysfunction in elderly and senile patients with ischemic heart disease and heart failure. The Russian Archives of Internal Medicine. 2018;8(1):59-64 (in Russ.). DOI: 10.20514/2226-6704-2018-8-1-59-64
7. Nikolayev N.A., Skirdenko Yu.P. Russian generic questionnaire for evaluation of compliance to drug therapy. Clinical pharmacology and therapy. 2018;27(1):74-78 (in Russ.)
8. Rebrov A.P., Kosheleva N.A. Effect of therapeutic training and active outpatient management on clinical state and cardiovascular complications in patients with chronic heart failure (three year follow-up). Rational Pharmacotherapy in Cardiology. 2011;7(3): 275-287 (in Russ.). DOI: 10.20996/1819-6446-2011-7-3-275-287
9. Sitnikova M.Yu., Lyasnikova E.A., Yurchenko A.V., Trukshina M.A., Libis R.A.2, Kondratenko V.Yu., Duplyakov D.V. et al. Results of Russian hospital chronic heart failure registry in three subjects of Russian Federation. Kardiologiia. 2015;55(10):5-13 (in Russ.). DOI: 10.18565/cardio.2015.10.5-13
10. Sitnikova M.Yu., Lyasnikova E.A., Yurchenko A.V., Trukshina M.A., Kuular A.A., Galenko V.L., Ivanov S.G., Duplyakov D.V. et al. Results of 3 years work of the Russian hospital register of chronic heart failure (RUssian hoSpital Heart Failure Registry - RUS-HFR): relationship between management and outcomes in patients with chronic heart failure. Kardiologiia. 2018;58(10S): 9-19 (in Russ.). DOI: 10.18087/cardio.2483
11. Chukaeva I.I., Larina V.N., Karpenko D.G., Pozdnyakova A.V. Medication adherence of elderly patients with chronic heart failure. Kardiologiia. 2017;57(10):65-72 (in Russ.). DOI: 10.18087/cardio.2017.10.10043
12. Cavanagh C.E., Rosman L., Spatz E.S., Fried T., Gandhi P.U., Soucier R.J., Burg M.M. Dying to know: prognosis communication in heart failure. ESC Heart Fail. 2020;7(6):3452-3463. DOI: 10.1002/ehf2.12941
13. Currie K., Strachan P.H., Spaling M., Harkness K., Barber D., Clark A.M. The importance of interactions between patients and healthcare professionals for heart failure self-care: A systematic review of qualitative research into patient perspectives. Eur J Cardiovasc Nurs. 2015;14(6):525-535. DOI: 10.1177/1474515114547648
14. De Geest S., Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323. DOI: 10.1016/S1474-5151(03)00091-4
15. Dodson J.A., Truong T.T., Towle V.R., Kerins G., Chaudhry S.I. Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. Am J Med. 2013;126(2):120-126. DOI: 10.1016/j.amjmed.2012.05.029
16. Gallagher A.M., Lucas R., Cowie M.R. Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach. ESC Heart Fail. 2019;6(1):3-9. DOI: 10.1002/ehf2.12363
17. Greene S.J., Butler J., Albert N.M., DeVore A.D., Sharma P.P., Duffy C.I., Hill C.L., McCague K. et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351-366. DOI: 10.1016/j.jacc.2018.04.070
18. Haynes S.C., Tancredi D.J., Tong K., Hoch J.S., Ong M.K., Ganiats T.G., Evangelista L.S., Black J.T. et al. Association of Adherence to Weight Telemonitoring With Health Care Use and Death: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2020;3(7):e2010174. DOI: 10.1001/jamanetworkopen.2020.10174
19. Jelínek L., Václavík J., Ramík Z., Pavlů L., Benešová K., Jarkovský J., Lazárová M., Janečková H. et al. Directly Measured Adherence to Treatment in Chronic Heart Failure: LEVEL-CHF Registry. Am J Med Sci. 2021;361(4):491-498. DOI: 10.1016/j.amjms.2020.12.004
20. JMIR Publications. What is your policy regarding access to critical research tools and instruments (eg, questionnaires)? (2018). URL: https://jmir.zendesk.com/hc/en-us/articles/360000547811
21. Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020;(9):2019-11-3. DOI: 10.7573/dic.2019-11-3
22. Ketilsdottir A., Ingadottir B., Jaarsma T. Self-reported health and quality of life outcomes of heart failure patients in the aftermath of a national economic crisis: a cross-sectional study. ESC Heart Fail. 2019;6(1):111-121. DOI: 10.1002/ehf2.12369
23. Kocabaş U., Kıvrak T., Yılmaz Öztekin G.M., Tanık V.O., Özdemir I.H., Kaya E., Yüce E.I., Avcı Demir F. et al. Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study. Anatol J Cardiol. 2020;24(1):32-40. DOI: 10.14744/AnatolJCardiol.2020.91771
24. Lauffenburger J.C., Khan N.F., Brill G., Choudhry N.K. Quantifying Social Reinforcement Among Family Members on Adherence to Medications for Chronic Conditions: a US-Based Retrospective Cohort Study. J Gen Intern Med. 2019;34(6):855-861. DOI: 10.1007/s11606-018-4654-9
25. Makris E., Hu L., Jones G.B., Wright J.M. Moving the Dial on Heart Failure Patient Adherence Rates. Patient Prefer Adherence. 2020;(14):2407-2418. DOI: 10.2147/PPA.S283277
26. Marcus A. Pay up or retract? Drug survey spurs conflict. Science. 2017;357(6356):1085-1086. DOI: 10.1126/science.357.6356.1085
27. Matsuo Y., Yoshimine F., Fuse K., Suzuki K., Sakamoto T., Iijima K., Ozaki K., Minamino T. Regional Disparities in Adherence to Guidelines for the Treatment of Chronic Heart Failure. Intern Med. 2021;60(4):525-532. DOI: 10.2169/internalmedicine.4660-20
28. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368
29. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L., Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. DOI: 10.1056/NEJMoa1911303
30. Moon S.J., Lee W.Y., Hwang J.S., Hong Y.P., Morisky D.E. Accuracy of a screening tool for medication adherence: A systematic review and metaanalysis of the Morisky Medication Adherence Scale-8. PLoS One. 2017;12(11):e0187139. DOI: 10.1371/journal.pone.0187139
31. Packer M., Anker S.D., Butler J., Filippatos G., Ferreira J.P., Pocock S.J., Carson P., Anand I. et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326-336. DOI: 10.1161/CIRCULATIONAHA.120.051783
32. Packer M., Metra M. Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. Eur J Heart Fail. 2020;22(10):1759-1767. DOI: 10.1002/ejhf.1857
33. Savarese G., Lund L.H. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. DOI: 10.15420/cfr.2016:25:2
34. Son Y.J., Choi J., Lee H.J. Effectiveness of Nurse-Led Heart Failure Self-Care Education on Health Outcomes of Heart Failure Patients: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020;17(18):6559. DOI: 10.3390/ijerph17186559
35. Tomasoni D., Adamo M., Anker M.S., von Haehling S., Coats A.J.S., Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;7(6):3505-3530. DOI: 10.1002/ehf2.13124
36. Valk M.J.M., Hoes A.W., Mosterd A., Landman M.A., Zuithoff N.P.A., Broekhuizen B.D.L., Rutten F.H. Training general practitioners to improve evidence-based drug treatment of patients with heart failure: a cluster randomised controlled trial. Neth Heart J. 2020;28(11):604-612. DOI: 10.1007/s12471-020-01487-x
37. Verma S., Anker S.D., Butler J., Bhatt D.L. Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective. ESC Heart Fail. 2020;7(6):3261-3267. DOI: 10.1002/ehf2.13148
38. Wirtz H.S., Sheer R., Honarpour N., Casebeer A.W., Simmons J.D., Kurtz C.E., Pasquale M.K., Globe G. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure. J Am Heart Assoc. 2020;9(16):e015042. DOI: 10.1161/JAHA.119.015042
Review
For citations:
Meshcherina N.S., Khardikova E.M., Gorshunova N.K., Abrosimova N.V., Leontieva T.S. The role of compliance in the treatment of chronic heart failure and the ways to improve it. Humans and their health. 2021;24(3):4-13. (In Russ.) https://doi.org/10.21626/vestnik/2021-3/01
Views:
481
Email this article 